goal
immunosuppress
therapi
dampen
immun
respons
time
transplant
unfortun
agent
specif
target
immun
respons
transplant
organ
result
protect
function
human
immun
system
jeopard
among
bodi
abil
neutral
malignantli
transform
cell
particularli
driven
viral
infect
one
longrecogn
side
effect
immunosuppress
increas
risk
select
malign
common
malign
among
transplant
recipi
nonmelanomat
skin
cancer
may
affect
nearli
quarter
liver
transplant
recipi
lifethreaten
cancer
howev
present
elev
rate
patient
popul
gener
involv
gastrointestin
gi
tract
particular
gi
malign
human
papillomaviru
tabl
recent
analysi
solid
organ
transplant
recipi
use
us
organ
procur
transplant
network
optn
unit
network
organ
share
uno
databas
overal
incid
posttransplant
malign
liver
transplant
recipi
gi
cancer
whole
common
type
regardless
malign
type
standard
prevent
practic
eg
smoke
cessat
sun
protect
breast
selfexamin
routin
cancer
screen
examin
eg
chest
xray
colonoscopi
dermatolog
evalu
highli
encourag
transplant
incorpor
posttransplant
manag
pathway
recipi
specif
transplant
popul
collect
lymphoid
malign
known
posttransplant
lymphoprolif
disord
ptld
singl
common
type
cancer
report
among
liver
transplant
recipi
recent
review
sampaio
et
al
ptld
differ
lymphoma
seen
immunocompet
patient
may
present
outsid
nodal
tissu
tend
aris
regress
rapidli
anoth
complic
immunosuppress
therapi
develop
posttransplant
infect
vast
major
infect
occur
within
first
month
transplant
intens
immunosuppress
highest
howev
infect
may
happen
time
gener
occur
predict
pattern
transplant
tabl
common
lifethreaten
opportunist
infect
address
detail
chapter
long
term
risk
infect
persist
still
directli
relat
patient
level
immunosuppress
thu
patient
undergo
treatment
reject
remain
high
risk
infect
even
therapi
ceas
although
seriou
bacteri
fungal
infect
predomin
earli
transplant
viral
condit
prevail
long
term
includ
reactiv
latent
herp
virus
includ
cytomegaloviru
cmv
ebv
herp
simplex
herp
zoster
relationship
reactiv
lead
mani
reinstitut
viralspecif
prophylaxi
treat
reject
eg
ganciclovir
hepat
c
recurr
ubiquit
infect
individu
although
phenotyp
recurr
vari
consider
asymptomat
carrier
state
rapid
hepat
deterior
primari
approach
condit
includ
reduct
immunosuppress
addit
target
antivir
therapi
hepat
c
nearli
antivir
agent
develop
hepat
c
variou
experiment
phase
two
recent
approv
agent
boceprevir
telaprevir
proteas
inhibitor
use
combin
pegyl
interferon
ribavirin
shown
improv
cure
rate
shorter
durat
therapi
although
immunocompromis
state
princip
reason
behind
posttransplant
infect
attent
periop
factor
may
help
mitig
risk
includ
minim
immunosuppress
recipi
ill
decondit
overcom
recent
infect
hospit
time
transplant
specif
issu
common
patient
recov
hepat
failur
includ
hypogammaglobulinemia
leukocytopenia
recogn
clue
limit
immunosuppress
load
maneuv
thwart
potenti
infect
transplant
includ
treat
donorrel
infect
take
precaut
health
careassoci
bacteri
infect
ie
surgic
site
catheterassoci
urinari
tract
infect
ventilatorassist
pneumonia
provid
prophylaxi
potenti
opportunist
infect
via
routin
use
antimicrobi
trimethoprimsulfamethoxazol
amphotericin
ganciclovir
pioneer
studi
found
corticosteroid
css
could
prolong
skin
graft
surviv
rabbit
fifti
year
ago
starzl
et
al
show
cs
along
azathioprin
aza
extend
patient
graft
surviv
kidney
transplant
today
css
remain
cornerston
immunosuppress
therapi
induct
agent
time
transplant
puls
agent
treatment
posttransplant
reject
episod
longterm
consequ
cs
use
numer
well
known
tabl
focu
common
complic
cs
use
liver
transplant
wellknown
complic
longterm
cs
use
diabet
occur
adult
liver
transplant
recipi
csinduc
diabet
result
impair
glucos
metabol
increas
insulin
resist
mechan
result
hyperglycemia
includ
reduct
insulin
product
increas
gluconeogenesi
decreas
peripher
glucos
util
reduc
glycogen
synthesi
effect
thought
dose
depend
reduc
dose
cs
shown
decreas
insulin
resist
addit
css
enhanc
appetit
particularli
sweeten
food
describ
later
calcineurin
inhibitor
cni
contribut
significantli
develop
posttransplant
diabet
mellitu
ptdm
even
though
mani
program
employ
steroid
avoid
lowmaintenancedos
cs
protocol
ptdm
remain
consider
problem
thu
one
extrapol
ptdm
primarili
due
cni
preval
dyslipidemia
document
liver
transplant
recipi
mechan
mechan
lead
dyslipidemia
clear
may
due
steroidinduc
insulin
resist
lead
increas
level
verylowdens
lipoprotein
vldl
triglycerid
lowdens
lipoprotein
ldl
lipogenesi
may
also
pronounc
cs
use
endocrin
complic
describ
diabet
dyslipidemia
increas
risk
cardiovascular
event
transplant
anoth
risk
factor
contribut
cardiac
diseas
hypertens
mechan
involv
caus
increas
blood
pressur
includ
sodium
water
retent
distal
nephron
upregul
receptor
present
vascular
smooth
muscl
contribut
involv
pathway
central
nervou
system
adipos
tissu
liver
liver
transplant
recipi
previous
diagnos
hypertens
may
develop
elev
blood
pressur
transplant
one
medic
tackl
mechan
list
earlier
use
calcium
channel
blocker
diuret
merit
may
prove
effect
firstlin
therapi
musculoskelet
complic
prolong
cs
use
devast
cs
use
lead
caus
secondari
druginduc
osteoporosi
bone
metabol
affect
sever
pathway
mainli
suppress
osteoblast
prolifer
activ
stimul
osteoclast
induc
bone
resorpt
decreas
calcium
absorpt
gi
tract
increas
urinari
calcium
excret
bone
loss
due
cs
use
greater
trabecular
bone
compar
cortic
bone
thu
risk
fractur
greatest
vertebr
bodi
rib
femor
head
liver
transplant
candid
risk
osteoporosi
fractur
alreadi
elev
due
effect
chronic
diseas
medic
immobil
common
risk
factor
seen
liver
transplant
recipi
includ
advanc
age
increas
bodi
weight
femal
sex
specif
postmenopaus
women
incid
fractur
transplant
recipi
highest
within
first
month
transplant
document
rate
rang
fractur
may
even
occur
dose
low
mg
prednison
daili
fortun
risk
bone
loss
dose
depend
likelihood
fractur
rapidli
decreas
css
discontinu
measur
prevent
manag
osteoporosi
discuss
elsewher
textbook
center
posttransplant
patient
place
supplement
calcium
vitamin
numer
side
effect
css
attempt
made
reduc
remov
css
standard
posttransplant
immunosuppress
regimen
center
steroid
elimin
within
week
transplant
major
recipi
except
autoimmun
etiolog
autoimmun
hepat
primari
scleros
cholang
primari
biliari
cirrhosi
complet
elimin
may
result
earli
flare
underli
diseas
elimin
css
complet
armamentarium
unlik
although
link
mani
longterm
effect
css
effect
agent
result
success
transplant
ideal
immunosuppress
agent
regimen
found
transplant
center
immunosuppress
regimen
includ
cni
cyclosporin
cya
tacrolimu
tac
medic
new
immunosuppress
agent
compar
superior
seen
agent
respect
graft
patient
surviv
acut
graft
reject
overwhelm
sinc
approv
organ
transplant
nonetheless
cni
imperfect
wellknown
longterm
side
effect
princip
consid
immedi
side
effect
cni
neurotox
may
becom
appar
month
year
initi
addit
one
must
cogniz
side
effect
convert
patient
onto
cni
immunosuppress
anticip
rise
cni
level
face
drug
interact
thu
potenti
harm
consequ
merit
attent
frequenc
cniinduc
neurotox
report
rang
gener
common
sever
tac
cya
mildest
form
neurotox
headach
migrain
fine
tremor
typic
respons
acetaminophen
headach
migrain
gener
respons
sumatriptan
imitrex
event
usual
dose
relat
revers
reduct
cni
symptom
persist
convers
tac
cya
anoth
agent
may
necessari
opposit
end
spectrum
sever
side
effect
includ
cognit
chang
psychosi
hallucin
postur
opisthotonu
seizur
activ
coma
sever
consequ
cni
neurotox
posterior
revers
encephalopathi
syndrom
pre
condit
consist
sever
neurolog
deficit
magnet
reson
imag
find
cortic
subcort
cytotox
edema
whether
cni
trough
level
elev
cni
discontinu
immedi
furthermor
sever
neurolog
complic
correl
cni
level
suggest
idiosyncrat
respons
serum
magnesium
monitor
supplement
recommend
potenti
fatal
extrem
circumst
cniinduc
neurotox
gener
revers
function
recoveri
may
requir
month
cniassoci
nephrotox
describ
earli
use
cya
bone
marrow
transplant
surprisingli
administ
dose
cya
mani
time
greater
mgkg
recommend
today
studi
anim
human
biopsi
tissu
confirm
variou
patholog
chang
nephron
caus
cya
strike
vasculopathi
affer
arteriol
result
intim
fibrosi
eventu
glomerular
collaps
nephropathi
seen
today
fig
practic
purpos
tac
cya
equal
nephrotox
develop
sever
chronic
kidney
diseas
solid
organ
transplant
uncov
two
landmark
paper
first
gonwa
et
al
demonstr
declin
renal
function
measur
glomerular
filtrat
rate
month
liver
transplant
recipi
without
renal
dysfunct
next
ojo
et
al
found
cumul
incid
chronic
renal
failur
liver
transplant
recipi
nearli
year
sinc
major
focu
field
transplant
identifi
address
caus
periop
renal
dysfunct
top
list
nephrotox
effect
cni
princip
stimulu
develop
new
immunosuppress
agent
recogn
longterm
side
effect
associ
cni
posttransplant
hyperlipidemia
diabet
hypertens
element
metabol
syndrom
cours
factor
predispos
transplant
recipi
risk
includ
race
age
unrecogn
preexist
diseas
bodi
mass
index
cs
use
name
consequ
ultim
contribut
increas
cardiovascular
morbid
mortal
seen
longterm
thu
earli
screen
intervent
may
aid
reduc
risk
preval
hyperlipidemia
transplant
upward
multipl
studi
cni
associ
side
effect
css
postul
mechan
cnirel
hyperlipidemia
includ
bind
ldl
receptor
increas
serum
ldl
decreas
activ
lipoprotein
lipas
increas
serum
vldl
ldl
inhibit
bile
acid
synthesi
lead
increas
cholesterol
ptdm
seen
upward
liver
transplant
recipi
cni
caus
ptdm
inhibit
insulin
secret
pancreat
cell
tac
significantli
diabetogen
cya
metaanalysi
compar
effect
tac
cya
renal
transplant
tactreat
patient
significantli
increas
risk
newonset
ptdm
compar
cyatreat
patient
rel
risk
year
increas
risk
increas
tac
trough
concentr
also
african
american
increas
risk
rel
white
combin
cni
cs
exacerb
predilect
glucos
intoler
preval
posttransplant
hypertens
also
high
patient
take
cni
one
earli
studi
liver
transplant
recipi
take
either
cya
tac
elev
blood
pressur
mm
hg
seen
patient
first
month
liver
transplant
modern
incid
like
lower
reduc
dose
cni
use
cs
use
minim
nonetheless
treat
hypertens
liver
transplant
norm
mechan
caus
cniinduc
hypertens
includ
sodium
retent
decreas
product
vasodil
substanc
nitric
oxid
prostacyclin
renal
vasoconstrict
undesir
outcom
associ
cya
includ
acn
hirsut
gingiv
hyperplasia
unfavor
aesthet
result
may
lead
patient
request
chang
cya
tac
lesser
risk
consequ
tabl
outlin
common
side
effect
cni
sirolimu
srl
discov
approv
food
drug
administr
kidney
transplant
demonstr
lack
direct
nephrotox
neurotox
properti
offlabel
use
liver
transplant
follow
suggest
benefit
recipi
hepatocellular
carcinoma
hepat
c
recent
everolimu
evr
introduc
recent
approv
food
drug
administr
use
kidney
transplant
trial
liver
transplant
way
despit
known
benefit
mammalian
target
rapamycin
mtor
inhibitor
set
longterm
consequ
review
random
control
trial
subject
increas
cholesterol
triglycerid
level
shown
associ
mtor
inhibitor
use
roughli
twice
mani
recipi
mtor
inhibitor
treat
lipidlow
agent
caus
dyslipidemia
may
increas
plasma
level
apolipoprotein
result
elev
vldl
ldl
level
interestingli
whether
translat
increas
atherosclerot
diseas
support
srl
shown
reduc
atherosclerosi
anim
model
recent
studi
mckenna
et
al
liver
transplant
recipi
de
novo
srl
similar
incid
cardiovascular
event
eg
myocardi
infarct
stroke
transplant
control
patient
never
srl
despit
statist
higher
total
cholesterol
triglycerid
level
significantli
higher
framingham
risk
score
srl
cohort
thu
despit
caus
dyslipidemia
srl
may
cardioprotect
properti
stem
immun
modul
variou
pathway
caus
atherosclerosi
although
mtor
inhibitor
caus
renal
tubular
dysfunct
associ
higher
incid
proteinuria
gener
marker
chronic
renal
diseas
document
kidney
transplant
de
novo
use
also
earli
late
convers
transplant
longterm
implic
proteinuria
de
novo
use
unknown
howev
among
kidney
transplant
patient
convert
srl
gutierrez
et
al
found
patient
baselin
proteinuria
greater
mgdl
along
greater
degre
renal
insuffici
higher
risk
proteinuria
progress
renal
dysfunct
although
mention
potenti
complic
earli
trial
srl
proteinuria
clearli
document
evr
approv
kidney
transplant
mechan
srl
caus
accentu
proteinuria
yet
defin
howev
angiotensinconvert
enzym
inhibitor
statin
shown
reduc
proteinuria
patient
renal
dysfunct
one
studi
suggest
therapi
effect
limit
mtor
inhibitorinduc
proteinuria
patient
consid
srl
convers
assess
preexist
proteinuria
urin
collect
proteinuria
less
mgday
renal
dysfunct
revers
convers
cni
srl
patient
establish
proteinuria
mgday
convers
srl
may
exacerb
exist
proteinuria
acceler
renal
dysfunct
therefor
patient
maintain
low
level
cni
late
convers
year
transplant
srl
usual
improv
renal
function
instead
may
exacerb
renal
dysfunct
patient
take
mtor
inhibitor
known
increas
risk
develop
wound
complic
antiprolif
mechan
thought
produc
benefici
oncolog
effect
eg
hepatocellular
carcinoma
may
also
account
poor
woundheal
properti
limit
fibroblast
prolifer
exampl
wound
complic
includ
tracheal
dehisc
lung
transplant
recipi
increas
occurr
lymphocel
kidney
transplant
recipi
literatur
assess
wound
complic
liver
transplant
plenti
earli
experi
srl
liver
transplant
confirm
wound
infect
dehisc
frequent
howev
initi
trial
srl
use
higher
dose
trough
level
gener
use
today
one
random
control
trial
look
efficaci
evr
trend
incision
hernia
evr
arm
versu
p
recent
protect
studi
evr
liver
transplant
increas
woundheal
problem
note
baylor
simmon
transplant
institut
vast
experi
use
srl
liver
transplant
patient
de
novo
convers
therapi
rate
wound
complic
includ
develop
incision
hernia
anecdot
high
current
review
transplant
patient
de
novo
srl
incis
monitor
care
incisionlin
wound
vacuumassist
closur
assist
wound
heal
longterm
recipi
develop
incision
hernia
take
srl
precaut
taken
herniorrhaphi
convert
patient
srl
onto
cni
week
repair
reinstitut
srl
discontinu
cni
least
week
repair
wound
heal
complet
convers
carri
minim
concern
reject
note
convers
back
srl
requir
readdit
secondari
agent
eg
mycophenol
aza
srl
monotherapi
practic
center
oral
ulcer
common
side
effect
mtor
inhibitor
affect
patient
take
medic
also
occur
late
longterm
use
often
mistaken
oral
herp
simplex
viru
infect
ulcer
pain
one
common
reason
discontinu
current
manag
involv
topic
steroid
combin
dental
past
eg
kenalog
orabas
appli
directli
ulcer
secondarili
dose
mtor
inhibitor
reduc
anoth
troublesom
consequ
seen
use
mtor
inhibitor
bone
marrow
suppress
name
leukopenia
anemia
may
amelior
via
dose
reduct
treatment
ie
filgrastim
neupogen
inject
iron
supplement
transfus
srl
also
associ
atyp
noninfecti
pneumon
rare
seen
today
approxim
patient
side
effect
frequent
observ
higher
dose
srl
initi
experi
recogn
treat
srl
discontinu
categor
antimetabolit
aza
purin
analogu
inhibit
purin
nucleotid
thu
dna
synthesi
inhibit
prolifer
fastgrow
cell
b
cell
aza
first
introduc
transplant
nearli
year
ago
along
glucocorticoid
standard
regimen
liver
kidney
transplant
introduct
cya
would
use
secondari
agent
thereaft
replac
anoth
antimetabolit
mycophenol
mofetil
mmf
longterm
toxic
associ
aza
use
includ
hematolog
defici
gi
disturb
hypersensit
reaction
includ
skin
rash
immunosuppress
agent
aza
associ
develop
malign
name
increas
risk
skin
cancer
aza
shown
enhanc
develop
ultravioletinduc
carcinogenesi
aza
still
remain
viabl
altern
immunosuppress
therapi
dose
low
mg
daili
recent
comparison
aza
mmf
result
favor
evalu
former
systemat
review
random
control
trial
compar
agent
kidney
transplant
show
lesser
occurr
giadvers
event
diarrhea
emesi
abdomin
pain
leukopenia
anemia
cmv
infect
aza
group
similar
rate
malign
aza
mmf
anoth
review
compar
agent
liver
transplant
germani
et
al
found
signific
benefit
mmf
aza
antireject
agent
use
cya
interestingli
studi
rate
hepat
c
viru
recurr
sever
frequent
report
aza
find
alreadi
note
wiesner
et
al
intern
multicent
compar
studi
aza
mmf
unavoid
corollari
merit
discuss
cost
use
aza
mmf
indisput
would
favor
aza
analysi
costeffect
would
need
undertaken
prove
point
intuit
aza
afford
option
mmf
anoth
purin
synthesi
inhibitor
essenti
replac
aza
complementari
immunosuppress
agent
cni
earli
cniinduc
toxic
curtail
ad
mmf
steroid
withdrawn
earlier
liver
transplant
common
side
effect
associ
mmf
gi
natur
includ
nausea
vomit
diarrhea
abdomin
cramp
anorexia
lead
mmf
reduct
withdraw
case
activ
form
mmf
mycophenol
acid
mpa
develop
entericco
mycophenol
sodium
attempt
improv
gi
toler
sinc
releas
studi
confirm
therapeut
equival
compar
mmf
importantli
benefit
girel
symptom
overwhelmingli
shown
anoth
side
effect
mmf
myelosuppress
usual
form
leukopenia
less
commonli
anemia
effect
revers
howev
appear
dose
relat
whether
gi
hematolog
advers
event
mmf
may
address
dose
split
ie
chang
dose
mg
twice
daili
mg
four
time
daili
dose
reduct
discontinu
mmf
entericco
mycophenol
sodium
usual
prescrib
conjunct
agent
strongli
implic
increas
incid
infect
howev
patient
use
mpa
psoriasi
multipl
report
case
herp
zoster
reactiv
also
document
among
kidney
transplant
recipi
receiv
mpa
studi
spain
among
adult
liver
transplant
patient
mmf
monotherapi
common
advers
effect
herp
simplex
infect
thu
may
link
mmf
use
varicella
infect
gener
mmf
safe
effect
agent
prevent
organ
transplant
reject
unlik
agent
longterm
toxic
cumul
transplant
program
use
antibodi
therapi
target
b
cell
immedi
periop
period
thwart
reject
respons
recipi
agent
cover
depth
chapter
acut
toxic
longterm
complic
induct
agent
becom
recogn
lead
reduct
use
center
howev
still
use
atyp
steroidresist
reject
antithymocyt
globulin
atg
rabbit
atg
thymoglobulin
routin
use
induct
agent
liver
transplant
still
use
treatment
steroidresist
reject
short
term
atg
administr
associ
side
effect
includ
flulik
symptom
term
cytokin
releas
syndrom
character
sever
case
tachycardia
dyspnea
chest
pain
pulmonari
edema
fever
premed
acetaminophen
antihistamin
steroid
usual
amelior
symptom
syndrom
preval
first
dose
abat
repeat
dose
serum
sick
manifest
urticari
rash
arthralgia
occur
patient
particularli
prior
exposur
atg
typic
emerg
sever
dose
given
pancytopenia
also
commonli
seen
report
publish
regard
longterm
followup
patient
receiv
atg
induct
agent
liver
transplant
studi
suggest
increas
risk
infecti
complic
malign
transplant
receptor
inhibitor
basiliximab
daclizumab
inert
agent
caus
neither
infusionrel
phenomena
untoward
longterm
side
effect
nephrotox
earli
studi
liver
transplant
focus
abil
provid
effect
earli
immunosuppress
recipi
renal
dysfunct
allow
delay
introduct
cni
addit
daclizumab
shown
effect
reduc
acut
reject
episod
avoid
steroid
therapi
howev
basiliximab
show
signific
improv
convent
immunosuppress
regimen
metaanalysi
random
trial
interleukin
blocker
evid
increas
infect
malign
note
transplant
final
multicent
trial
klintmalm
et
al
addit
daclizumab
immunosuppress
regimen
hepat
c
patient
show
clear
benefit
standard
treatment
result
longer
use
induct
agent
steroid
patient
viral
hepat
alemtuzumab
recombin
monoclon
antibodi
gener
profound
deplet
circul
band
tcell
lymphocyt
macrophag
natur
killer
cell
effect
last
week
result
use
increasingli
recent
year
prevent
reject
organ
transplant
recipi
convers
concern
risk
infect
malign
due
mechan
action
review
patient
receiv
variou
organ
transplant
liver
transplant
n
univers
pittsburgh
alemtuzumab
use
treatment
reject
shown
caus
opportunist
infect
name
cmv
alemtuzumab
use
induct
therapi
multicent
studi
kidney
transplant
alemtuzumab
evalu
patient
receiv
convent
therapi
ie
rabbit
atg
basiliximab
induct
incid
malign
higher
alemtuzumab
group
p
rate
seriou
advers
infecti
event
alemtuzumab
greater
compar
basiliximab
versu
p
similar
compar
atg
liver
transplant
scant
literatur
longterm
effect
antibodi
howev
recent
retrospect
studi
nonhepat
c
recipi
receiv
alemtuzumab
found
greater
incid
infect
specif
viral
compar
receiv
induct
incid
malign
differ
group
holi
grail
immunosuppress
therapi
yet
discov
time
must
understand
potenti
complic
current
immunosuppress
medic
proper
identif
manag
treatment
side
effect
improv
outcom
liver
transplant
recipi
achiev
knowledg
understand
longterm
side
effect
immunosuppress
lead
earli
detect
treatment
potenti
complic
identif
treatment
posttransplant
lymphoprolif
disord
requir
suspicion
diagnosi
prompt
reduct
immunosuppress
medic
earli
oncolog
evalu
skin
cancer
common
malign
liver
transplant
precaut
sunscreen
protect
cover
dermatolog
evalu
follow
prolong
corticosteroid
calcineurin
inhibitor
use
contribut
increas
cardiovascular
morbid
eg
hypertens
hyperlipidemia
hyperglycemia
mortal
manag
issu
incorpor
patient
gener
mainten
plan
earli
mitig
longterm
effect
despit
establish
nephrotox
risk
renal
failur
calcineurin
inhibitor
tacrolimu
cyclosporin
remain
gold
standard
oral
immunosuppress
agent
target
rapamycin
mtor
inhibitor
consid
earli
convers
therapi
recipi
renal
dysfunct
dyslipidemia
proteinuria
wound
complic
wellknown
side
effect
thymoglobulin
lesser
degre
alemtuzumab
associ
infusionrel
symptom
collect
refer
cytokin
releas
syndrom
fever
chest
pain
dyspnea
tachycardia
requir
appropri
premed
vigil
administr
particularli
patient
limit
cardiovascular
reserv
